Search by Drug Name or NDC
NDC 25021-0253-50 Cisplatin 1 mg/mL Details
Cisplatin 1 mg/mL
Cisplatin is a INTRAVENOUS INJECTION, SOLUTION in the HUMAN PRESCRIPTION DRUG category. It is labeled and distributed by Sagent Pharmaceuticals. The primary component is CISPLATIN.
MedlinePlus Drug Summary
Cisplatin is used combination with other medications to treat cancer of the testicles that has not improved or that has worsened after treatment with other medications or radiation therapy. Cisplatin is used alone or in combination with other medications to treat cancer of the ovaries (cancer that begins in the female reproductive organs where eggs are formed) that has not improved or that has worsened after treatment with other medications or radiation therapy. Cisplatin is also used alone or in combination with other medications to treat bladder cancer that can not be treated with surgery or radiation therapy alone. Cisplatin is in a class of medications known as platinum-containing compounds. It works by stopping or slowing the growth of cancer cells.
Related Packages: 25021-0253-50Last Updated: 03/24/2024
MedLinePlus Full Drug Details: Cisplatin Injection
Product Information
| NDC | 25021-0253 |
|---|---|
| Product ID | 25021-253_64bcce1a-6e31-4e73-8da5-11aa9e890da2 |
| Associated GPIs | |
| GCN Sequence Number | 008785 |
| GCN Sequence Number Description | cisplatin VIAL 1 MG/ML INTRAVEN |
| HIC3 | V1A |
| HIC3 Description | ANTINEOPLASTIC - ALKYLATING AGENTS |
| GCN | 38920 |
| HICL Sequence Number | 003902 |
| HICL Sequence Number Description | CISPLATIN |
| Brand/Generic | Generic |
| Proprietary Name | Cisplatin |
| Proprietary Name Suffix | n/a |
| Non-Proprietary Name | Cisplatin |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Dosage Form | INJECTION, SOLUTION |
| Route | INTRAVENOUS |
| Active Ingredient Strength | 1 |
| Active Ingredient Units | mg/mL |
| Substance Name | CISPLATIN |
| Labeler Name | Sagent Pharmaceuticals |
| Pharmaceutical Class | Platinum-based Drug [EPC], Platinum-containing Compounds [EXT] |
| DEA Schedule | n/a |
| Marketing Category | ANDA |
| Application Number | ANDA207323 |
| Listing Certified Through | 2024-12-31 |
Package
NDC 25021-0253-50 (25021025350)
| NDC Package Code | 25021-253-50 |
|---|---|
| Billing NDC | 25021025350 |
| Package | 1 VIAL in 1 CARTON (25021-253-50) / 50 mL in 1 VIAL |
| Marketing Start Date | 2023-07-01 |
| NDC Exclude Flag | N |
| Pricing Information | N/A |